These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 23851698)

  • 21. From the potent and selective mu opioid receptor agonist H-Dmt-d-Arg-Phe-Lys-NH(2) to the potent delta antagonist H-Dmt-Tic-Phe-Lys(Z)-OH.
    Balboni G; Cocco MT; Salvadori S; Romagnoli R; Sasaki Y; Okada Y; Bryant SD; Jinsmaa Y; Lazarus LH
    J Med Chem; 2005 Aug; 48(17):5608-11. PubMed ID: 16107162
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and bioactivity of monobiotinylated DALDA: a mu-specific opioid peptide designed for targeted brain delivery.
    Bickel U; Yamada S; Pardridge WM
    J Pharmacol Exp Ther; 1994 Feb; 268(2):791-6. PubMed ID: 8113991
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833.
    Whiteside GT; Gottshall SL; Boulet JM; Chaffer SM; Harrison JE; Pearson MS; Turchin PI; Mark L; Garrison AE; Valenzano KJ
    Eur J Pharmacol; 2005 Dec; 528(1-3):65-72. PubMed ID: 16316650
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Opioid receptor binding characteristics and structure-activity studies of novel tetrapeptides in the TIPP (Tyr-Tic-Phe-Phe) series.
    Ioja E; Tóth G; Benyhe S; Tourwe D; Péter A; Tömböly C; Borsodi A
    Neurosignals; 2005; 14(6):317-28. PubMed ID: 16772734
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel sst(4)-selective somatostatin (SRIF) agonists. 1. Lead identification using a betide scan.
    Rivier J; Erchegyi J; Hoeger C; Miller C; Low W; Wenger S; Waser B; Schaer JC; Reubi JC
    J Med Chem; 2003 Dec; 46(26):5579-86. PubMed ID: 14667212
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel peptidic mu opioid antagonists: pharmacologic characterization in vitro and in vivo.
    Kramer TH; Shook JE; Kazmierski W; Ayres EA; Wire WS; Hruby VJ; Burks TF
    J Pharmacol Exp Ther; 1989 May; 249(2):544-51. PubMed ID: 2566679
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FE200041 (D-Phe-D-Phe-D-Nle-D-Arg-NH2): A peripheral efficacious kappa opioid agonist with unprecedented selectivity.
    Vanderah TW; Schteingart CD; Trojnar J; Junien JL; Lai J; Riviere PJ
    J Pharmacol Exp Ther; 2004 Jul; 310(1):326-33. PubMed ID: 14993260
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SNF9007: a novel analgesic that acts simultaneously at delta 1, delta 2 and mu opioid receptors.
    Williams CL; Rosenfeld GC; Dafny N; Fang SN; Hruby VJ; Bowden G; Cullinan CA; Burks TF
    J Pharmacol Exp Ther; 1994 May; 269(2):750-5. PubMed ID: 8182541
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The opioid mu agonist/delta antagonist DIPP-NH(2)[Psi] produces a potent analgesic effect, no physical dependence, and less tolerance than morphine in rats.
    Schiller PW; Fundytus ME; Merovitz L; Weltrowska G; Nguyen TM; Lemieux C; Chung NN; Coderre TJ
    J Med Chem; 1999 Sep; 42(18):3520-6. PubMed ID: 10479285
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis of new pyrimidine derivatives with evaluation of their anti-inflammatory and analgesic activities.
    Nofal ZM; Fahmy HH; Zarea ES; El-Eraky W
    Acta Pol Pharm; 2011; 68(4):507-17. PubMed ID: 21796933
    [TBL] [Abstract][Full Text] [Related]  

  • 31. De novo design, synthesis, and pharmacology of alpha-melanocyte stimulating hormone analogues derived from somatostatin by a hybrid approach.
    Han G; Haskell-Luevano C; Kendall L; Bonner G; Hadley ME; Cone RD; Hruby VJ
    J Med Chem; 2004 Mar; 47(6):1514-26. PubMed ID: 14998337
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel sst(4)-selective somatostatin (SRIF) agonists. 2. Analogues with beta-methyl-3-(2-naphthyl)alanine substitutions at position 8.
    Erchegyi J; Penke B; Simon L; Michaelson S; Wenger S; Waser B; Cescato R; Schaer JC; Reubi JC; Rivier J
    J Med Chem; 2003 Dec; 46(26):5587-96. PubMed ID: 14667213
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design of novel bicyclic analogues derived from a potent oxytocin antagonist.
    Flouret G; Chaloin O; Borovickova L; Slaninová J
    J Pept Sci; 2006 Jun; 12(6):412-9. PubMed ID: 16432806
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis and characterization of potent and selective mu-opioid receptor antagonists, [Dmt(1), D-2-Nal(4)]endomorphin-1 (Antanal-1) and [Dmt(1), D-2-Nal(4)]endomorphin-2 (Antanal-2).
    Fichna J; do-Rego JC; Chung NN; Lemieux C; Schiller PW; Poels J; Broeck JV; Costentin J; Janecka A
    J Med Chem; 2007 Feb; 50(3):512-20. PubMed ID: 17266203
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Opioid receptor selectivity of beta-endorphin in vitro and in vivo: mu, delta and epsilon receptors.
    Shook JE; Kazmierski W; Wire WS; Lemcke PK; Hruby VJ; Burks TF
    J Pharmacol Exp Ther; 1988 Sep; 246(3):1018-25. PubMed ID: 2843623
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Agonist and antagonist profiles of [D-Ala2,Glu4]deltorphin and its [Cys4]- and [Ser4]-substituted derivatives: further evidence of opioid delta receptor multiplicity.
    Horan PJ; Wild KD; Misicka A; Lipkowski A; Haaseth RC; Hruby VJ; Weber SJ; Davis TP; Yamamura HI; Porreca F
    J Pharmacol Exp Ther; 1993 May; 265(2):896-902. PubMed ID: 8388462
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design and synthesis of novel biologically active thrombin receptor non-peptide mimetics based on the pharmacophoric cluster Phe/Arg/NH2 of the Ser42-Phe-Leu-Leu-Arg46 motif sequence: platelet aggregation and relaxant activities.
    Alexopoulos K; Fatseas P; Melissari E; Vlahakos D; Roumelioti P; Mavromoustakos T; Mihailescu S; Paredes-Carbajal MC; Mascher D; Matsoukas J
    J Med Chem; 2004 Jun; 47(13):3338-52. PubMed ID: 15189031
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of putative agouti-related protein(87-132)-melanocortin-4 receptor interactions by homology molecular modeling and validation using chimeric peptide ligands.
    Wilczynski A; Wang XS; Joseph CG; Xiang Z; Bauzo RM; Scott JW; Sorensen NB; Shaw AM; Millard WJ; Richards NG; Haskell-Luevano C
    J Med Chem; 2004 Apr; 47(9):2194-207. PubMed ID: 15084118
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Studies on the synthesis and structure-activity relation of deltorphin I analogues].
    Hu XY; Wang R; Jia Q; Wang Q
    Yao Xue Xue Bao; 1995; 30(9):679-84. PubMed ID: 8701744
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of the binding of [3H][Dmt1]H-Dmt-D-Arg-Phe-Lys-NH2, a highly potent opioid peptide.
    Neilan CL; Janvey AJ; Bolan E; Berezowska I; Nguyen TM; Schiller PW; Pasternak GW
    J Pharmacol Exp Ther; 2003 Aug; 306(2):430-6. PubMed ID: 12663687
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.